• First Tracks Biotherapeutics reported positive top-line Phase 1b Cohort 1 results for ANB033 in celiac disease.
• The drug reduced gluten-driven intestinal injury versus placebo during a controlled gluten challenge, with symptom protection maintained throughout the exposure period.
• Tolerability looked favorable, with no serious or severe adverse events reported in the treated group.
• Results are slated for presentation at ICDS in Melbourne in November.
• The company expects to start a late-stage celiac trial in 2027, with additional Phase 1b data in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Tracks Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120700PRIMZONEFULLFEED9843644) on October 12, 2026, and is solely responsible for the information contained therein.